Associate Professor, Harvard Medical School
Director, Neuroimmunology Clinic and Research Laboratory
Department of Neurology, Massachusetts General Hospital
My fellow, @AVishnevetsky spends most of her time solving NMO and MOG. But in her spare time, she also saves Ukranian families!
https://t.co/m6MRyQ2FNN
FUNDING OPPORTUNITY ANNOUNCEMENT
The Sumaira Foundation is awarding research grants (maximum award up to $25,000) to fund research engaged in research into prevention, treatments, and a cure(s) for NMOSD and MOG-AD.
Deadline: September 16, 2022
https://t.co/M4qbkn9LAT
2022 Massachusetts Walk-Run-N-Roll for SRNA : Make a donation today to support 2022 Massachusetts Walk-Run-N-Roll for SRNA https://t.co/KRR5ITsin5 #Massachusetts-walkrunnroll-for-srna via @raisely
I recently recorded another podcast - How to avoid a misdiagnosis - MS, NMOSD & MOGAD.
https://t.co/7dqEW10sQg
@wearesrna@TheSumairaFDN @guthyjacksonfdn
Hear my update on our MOG Initiative at MGH, and learn about the first-ever MOG Antibody Disease trial:
https://t.co/X0IXOAb1uv
@MGHNeurology@TheMOGProject@TheSumairaFDN
The MGH NMO Clinic and Research Lab
announces 2 grants from the Sumaira Foundation!
- to examine how cholesterol pathways influence MOG-AD activity
- to create a simple, inexpensive NMO test for use in developing countries
#mghneurology#NMO#MOG#sumairafoundation
Do you or anyone you know have MOG antibody disease? Take this survey to help us assess the most effective treatments:
https://t.co/jozIlMWL6y
@MGHNeurology
I am pleased to introduce the Superficial Siderosis Clinic and Research Laboratory at Massachusetts General Hospital. Please visit our new web page: https://t.co/gCe7cuDwxl
@MGHNeurology
A large study in China (including Wuhan area) found no increased risk of COVID-19 among MS and NMO patients. Out of 3,060 NMOSD patients, only 2 had COVID-19 pneumonia and both recovered.
https://t.co/Ai2vknY4UW
The Massachusetts General Hospital NMO Clinic and Research Laboratory website is now available in Mandarin and Spanish! See options in the right-hand bar. https://t.co/PNvXTB1H96
@MGHNeurology
MGH is the first site for Alexion’s Ultomiris trial in NMOSD. Ultomiris is a long acting version of Soliris, which requires an infusion every 2 weeks. Ultomiris would extend that to 8 weeks. The goal is to show that Ultomiris is as effective as Soliris. [email protected].
Take advantage of this #GivingTuesday to make a donation to the new NMO Clinic and Research Lab at Mass General Hospital! https://t.co/mWSLkRQfU4 Thank you for all you do! #mgh